{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:51:22Z","timestamp":1794433882345,"version":"4.9.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1C1C1003652; 2021R1I1A3041149; RS-2026-25476540"],"award-info":[{"award-number":["2020R1C1C1003652; 2021R1I1A3041149; RS-2026-25476540"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00357518"],"award-info":[{"award-number":["RS-2024-00357518"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022M3E5F2017607"],"award-info":[{"award-number":["2022M3E5F2017607"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-NR077221; RS-2025-02214748"],"award-info":[{"award-number":["RS-2023-NR077221; RS-2025-02214748"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02796-0","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:01:55Z","timestamp":1785366115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["p21-activated kinase 4 drives hepatic stellate cell activation and liver fibrosis through the phosphorylation of YAP at T428"],"prefix":"10.1038","volume":"11","author":[{"given":"Gil-Hwan","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunsoo","family":"Rho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Jung","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongdo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwang Chan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Joo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ri","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Yi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9472-6085","authenticated-orcid":false,"given":"Ekihiro","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5343-701X","authenticated-orcid":false,"given":"Sangkyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1693-8290","authenticated-orcid":false,"given":"Eun Ju","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5990-3863","authenticated-orcid":false,"given":"Chang Yeob","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"2796_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva, T. & Brenner, D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol. 18, 151\u2013166 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2796_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi, H. et al. Global burden of liver disease: 2023 update. J. Hepatol. 79, 516\u2013537 (2023).","journal-title":"J. Hepatol."},{"key":"2796_CR3","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","volume":"158","author":"RF Schwabe","year":"2020","unstructured":"Schwabe, R. F., Tabas, I. & Pajvani, U. B. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology 158, 1913\u20131928 (2020).","journal-title":"Gastroenterology"},{"key":"2796_CR4","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m, H. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. 67, 1265\u20131273 (2017).","journal-title":"J. Hepatol."},{"key":"2796_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389\u2013397.e310 (2015).","journal-title":"Gastroenterology"},{"key":"2796_CR6","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor, R. S. et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 158, 1611\u20131625.e1612 (2020).","journal-title":"Gastroenterology"},{"key":"2796_CR7","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559\u20131569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2796_CR8","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison, S. A. et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med. 29, 2919\u20132928 (2023).","journal-title":"Nat. Med."},{"key":"2796_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","volume":"82","author":"V Ratziu","year":"2025","unstructured":"Ratziu, V., Scanlan, T. S. & Bruinstroop, E. Thyroid hormone receptor-\u03b2 analogs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). J. Hepatol. 82, 375\u2013387 (2025).","journal-title":"J. Hepatol."},{"key":"2796_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2796_CR11","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal, A. J. et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N. Engl. J. Med. 392, 2089\u20132099 (2025).","journal-title":"N. Engl. J. Med."},{"key":"2796_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397\u2013411 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2796_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41575-025-01068-6","volume":"22","author":"RF Schwabe","year":"2025","unstructured":"Schwabe, R. F. & Brenner, D. A. Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease. Nat. Rev. Gastroenterol. Hepatol. 22, 481\u2013499 (2025).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2796_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3823","volume":"4","author":"I Mederacke","year":"2013","unstructured":"Mederacke, I. et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology. Nat. Commun. 4, 2823 (2013).","journal-title":"Nat. Commun."},{"key":"2796_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101223","volume":"7","author":"V Merens","year":"2025","unstructured":"Merens, V. et al. Hepatic stellate cell single cell atlas reveals a highly similar activation process across liver disease etiologies. JHEP Rep. 7, 101223 (2025).","journal-title":"JHEP Rep."},{"key":"2796_CR16","doi-asserted-by":"crossref","unstructured":"Kisseleva, T., Ganguly, S., Murad, R., Wang, A. & Brenner, D. A. Regulation of hepatic stellate cell phenotypes in metabolic dysfunction-associated steatohepatitis. Gastroenterology 169, 797\u2013812 (2025).","DOI":"10.1053\/j.gastro.2025.03.010"},{"key":"2796_CR17","doi-asserted-by":"publisher","first-page":"101421","DOI":"10.1016\/j.jhepr.2025.101421","volume":"7","author":"RF Schwabe","year":"2025","unstructured":"Schwabe, R. F., Tacke, F., Sugimoto, A. & Friedman, S. L. Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease. JHEP Rep. 7, 101421 (2025).","journal-title":"JHEP Rep."},{"key":"2796_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","volume":"7","author":"M Fu","year":"2022","unstructured":"Fu, M. et al. The Hippo signaling pathway and its implications in human health and diseases. Signal Transduct. Target Ther. 7, 376 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2796_CR19","doi-asserted-by":"publisher","first-page":"100031","DOI":"10.1016\/j.pharmr.2024.100031","volume":"77","author":"P Guo","year":"2025","unstructured":"Guo, P., Wan, S. & Guan, K. L. The Hippo pathway: Organ size control and beyond. Pharm. Rev. 77, 100031 (2025).","journal-title":"Pharm. Rev."},{"key":"2796_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-genet-120417-031621","volume":"52","author":"JR Misra","year":"2018","unstructured":"Misra, J. R. & Irvine, K. D. The Hippo Signaling Network and Its Biological Functions. Annu Rev. Genet 52, 65\u201387 (2018).","journal-title":"Annu Rev. Genet"},{"key":"2796_CR21","doi-asserted-by":"crossref","unstructured":"Harvey, K. F. & Tang, T. T. Targeting the Hippo pathway in cancer. Nat. Rev. Drug Discov. 24, 852\u2013869 (2025).","DOI":"10.1038\/s41573-025-01234-0"},{"key":"2796_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.340","volume":"4","author":"Y Wei","year":"2023","unstructured":"Wei, Y. et al. YAP\/TAZ: Molecular pathway and disease therapy. MedComm 4, e340 (2023).","journal-title":"MedComm"},{"key":"2796_CR23","doi-asserted-by":"crossref","unstructured":"He, X. et al. Myofibroblast YAP\/TAZ activation is a key step in organ fibrogenesis. JCI Insight 7, e146243 (2022).","DOI":"10.1172\/jci.insight.146243"},{"key":"2796_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jhep.2015.04.011","volume":"63","author":"I Mannaerts","year":"2015","unstructured":"Mannaerts, I. et al. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J. Hepatol. 63, 679\u2013688 (2015).","journal-title":"J. Hepatol."},{"key":"2796_CR25","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1097\/HEP.0000000000000326","volume":"77","author":"K Du","year":"2023","unstructured":"Du, K. et al. Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis. Hepatology 77, 1998\u20132015 (2023).","journal-title":"Hepatology"},{"key":"2796_CR26","doi-asserted-by":"crossref","unstructured":"Alsamman, S. et al. Targeting acid ceramidase inhibits YAP\/TAZ signaling to reduce fibrosis in mice. Sci. Transl. Med. 12, eaay8798 (2020).","DOI":"10.1126\/scitranslmed.aay8798"},{"key":"2796_CR27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","volume":"20","author":"A Totaro","year":"2018","unstructured":"Totaro, A., Panciera, T. & Piccolo, S. YAP\/TAZ upstream signals and downstream responses. Nat. Cell Biol. 20, 888\u2013899 (2018).","journal-title":"Nat. Cell Biol."},{"key":"2796_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s11658-025-00760-4","volume":"30","author":"Z Zhang","year":"2025","unstructured":"Zhang, Z. et al. Posttranslational modifications of YAP\/TAZ: molecular mechanisms and therapeutic opportunities. Cell Mol. Biol. Lett. 30, 83 (2025).","journal-title":"Cell Mol. Biol. Lett."},{"key":"2796_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0204-0","volume":"51","author":"SY Won","year":"2019","unstructured":"Won, S. Y., Park, J. J., Shin, E. Y. & Kim, E. G. PAK4 signaling in health and disease: defining the PAK4-CREB axis. Exp. Mol. Med. 51, 1\u20139 (2019).","journal-title":"Exp. Mol. Med."},{"key":"2796_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s42255-023-00957-x","volume":"6","author":"HC Yu","year":"2024","unstructured":"Yu, H. C. et al. p21-activated kinase 4 counteracts PKA-dependent lipolysis by phosphorylating FABP4 and HSL. Nat. Metab. 6, 94\u2013112 (2024).","journal-title":"Nat. Metab."},{"key":"2796_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40597-z","volume":"14","author":"MY Shi","year":"2023","unstructured":"Shi, M. Y. et al. p21-activated kinase 4 suppresses fatty acid \u03b2-oxidation and ketogenesis by phosphorylating NCoR1. Nat. Commun. 14, 4987 (2023).","journal-title":"Nat. Commun."},{"key":"2796_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51240-w","volume":"15","author":"D Wu","year":"2024","unstructured":"Wu, D. et al. PAK4 phosphorylates and inhibits AMPK\u03b1 to control glucose uptake. Nat. Commun. 15, 6858 (2024).","journal-title":"Nat. Commun."},{"key":"2796_CR33","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/jcsm.12774","volume":"12","author":"Y Mao","year":"2021","unstructured":"Mao, Y. et al. p21-activated kinase 4 phosphorylates peroxisome proliferator-activated receptor \u03a5 and suppresses skeletal muscle regeneration. J. Cachexia Sarcopenia Muscle 12, 1776\u20131788 (2021).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"2796_CR34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/hep.32384","volume":"76","author":"Y Mao","year":"2022","unstructured":"Mao, Y. et al. p21-activated kinase 4 inhibition protects against liver ischemia\/reperfusion injury: Role of nuclear factor erythroid 2-related factor 2 phosphorylation. Hepatology 76, 345\u2013356 (2022).","journal-title":"Hepatology"},{"key":"2796_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12502","volume":"7","author":"K Martin","year":"2016","unstructured":"Martin, K. et al. PAK proteins and YAP-1 signaling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis. Nat. Commun. 7, 12502 (2016).","journal-title":"Nat. Commun."},{"key":"2796_CR36","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.1093\/emboj\/17.22.6527","volume":"17","author":"A Abo","year":"1998","unstructured":"Abo, A. et al. PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia. EMBO J. 17, 6527\u20136540 (1998).","journal-title":"EMBO J."},{"key":"2796_CR37","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/nm.3282","volume":"19","author":"NC Henderson","year":"2013","unstructured":"Henderson, N. C. et al. Targeting of \u03b1v integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19, 1617\u20131624 (2013).","journal-title":"Nat. Med."},{"key":"2796_CR38","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41586-025-08677-w","volume":"640","author":"A Sugimoto","year":"2025","unstructured":"Sugimoto, A. et al. Hepatic stellate cells control liver zonation, size and functions via R-spondin 3. Nature 640, 752\u2013761 (2025).","journal-title":"Nature"},{"key":"2796_CR39","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.jhep.2020.04.044","volume":"73","author":"J Gao","year":"2020","unstructured":"Gao, J. et al. Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis. J. Hepatol. 73, 1144\u20131154 (2020).","journal-title":"J. Hepatol."},{"key":"2796_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn5228","volume":"10","author":"S Khanal","year":"2024","unstructured":"Khanal, S. et al. Glycolysis in hepatic stellate cells coordinates fibrogenic extracellular vesicle release spatially to amplify liver fibrosis. Sci. Adv. 10, eadn5228 (2024).","journal-title":"Sci. Adv."},{"key":"2796_CR41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1101\/gad.1843810","volume":"24","author":"B Zhao","year":"2010","unstructured":"Zhao, B., Li, L., Tumaneng, K., Wang, C. Y. & Guan, K. L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 24, 72\u201385 (2010).","journal-title":"Genes Dev."},{"key":"2796_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-110","volume":"13","author":"K Tu","year":"2014","unstructured":"Tu, K. et al. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol. Cancer 13, 110 (2014).","journal-title":"Mol. Cancer"},{"key":"2796_CR43","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.ccell.2017.10.016","volume":"32","author":"\u00c9 Cosset","year":"2017","unstructured":"Cosset, \u00c9 et al. Glut3 addiction is a druggable vulnerability for a molecularly defined subpopulation of glioblastoma. Cancer Cell 32, 856\u2013868.e855 (2017).","journal-title":"Cancer Cell"},{"key":"2796_CR44","doi-asserted-by":"publisher","first-page":"11230","DOI":"10.1074\/jbc.RA118.002715","volume":"293","author":"SW Plouffe","year":"2018","unstructured":"Plouffe, S. W. et al. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell. J. Biol. Chem. 293, 11230\u201311240 (2018).","journal-title":"J. Biol. Chem."},{"key":"2796_CR45","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.tibs.2020.08.012","volume":"46","author":"F Reggiani","year":"2021","unstructured":"Reggiani, F., Gobbi, G., Ciarrocchi, A. & Sancisi, V. YAP and TAZ are not identical twins. Trends Biochem. Sci. 46, 154\u2013168 (2021).","journal-title":"Trends Biochem. Sci."},{"key":"2796_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62566-4","volume":"16","author":"G Zhao","year":"2025","unstructured":"Zhao, G. et al. Nucleus-translocated glucokinase functions as a protein kinase to phosphorylate TAZ and promote tumor growth. Nat. Commun. 16, 7156 (2025).","journal-title":"Nat. Commun."},{"key":"2796_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Wnt\/\u03b2-catenin signaling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct. Target Ther. 7, 3 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2796_CR48","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1053\/j.gastro.2015.02.056","volume":"148","author":"SP Monga","year":"2015","unstructured":"Monga, S. P. \u03b2-Catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology 148, 1294\u20131310 (2015).","journal-title":"Gastroenterology"},{"key":"2796_CR49","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1053\/j.gastro.2012.07.115","volume":"143","author":"Y Chen","year":"2012","unstructured":"Chen, Y. et al. Hedgehog controls hepatic stellate cell fate by regulating metabolism. Gastroenterology 143, 1319\u20131329.e1311 (2012).","journal-title":"Gastroenterology"},{"key":"2796_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bbrc.2023.02.032","volume":"653","author":"K Kou","year":"2023","unstructured":"Kou, K. et al. Hypoxia-inducible factor 1\u03b1\/IL-6 axis in activated hepatic stellate cells aggravates liver fibrosis. Biochem. Biophys. Res. Commun. 653, 21\u201330 (2023).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2796_CR51","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.bbrc.2019.05.004","volume":"514","author":"H Liu","year":"2019","unstructured":"Liu, H. et al. Myofibroblast-specific YY1 promotes liver fibrosis. Biochem. Biophys. Res Commun. 514, 913\u2013918 (2019).","journal-title":"Biochem. Biophys. Res Commun."},{"key":"2796_CR52","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1478-3231.2010.02347.x","volume":"31","author":"BL Copple","year":"2011","unstructured":"Copple, B. L., Bai, S., Burgoon, L. D. & Moon, J. O. Hypoxia-inducible factor-1\u03b1 regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int. 31, 230\u2013244 (2011).","journal-title":"Liver Int."},{"key":"2796_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/pin.13410","volume":"74","author":"X Fu","year":"2024","unstructured":"Fu, X., Luo, X., Xiao, P. & Guo, N. Yin Yang 1 facilitates the activation, inflammation, and extracellular matrix deposition of hepatic stellate cells in hepatic fibrosis. Pathol. Int. 74, 197\u2013209 (2024).","journal-title":"Pathol. Int."},{"key":"2796_CR54","doi-asserted-by":"publisher","unstructured":"Geng, Y. & Schwabe, R. F. Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications. Hepatology https:\/\/doi.org\/10.1097\/HEP.0000000000001386 (2025).","DOI":"10.1097\/HEP.0000000000001386"},{"key":"2796_CR55","doi-asserted-by":"crossref","unstructured":"Lan, R. et al. Communication initiated by hepatocytes: the driver of HSC activation and liver fibrosis. Hepatol. Commun. 9, e0753 (2025).","DOI":"10.1097\/HC9.0000000000000753"},{"key":"2796_CR56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.trecan.2024.10.004","volume":"11","author":"S Paul","year":"2025","unstructured":"Paul, S., Sims, J., Pham, T. & Dey, A. Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors? Trends Cancer 11, 25\u201336 (2025).","journal-title":"Trends Cancer"},{"key":"2796_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46531-1","volume":"15","author":"I Baroja","year":"2024","unstructured":"Baroja, I., Kyriakidis, N. C., Halder, G. & Moya, I. M. Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer. Nat. Commun. 15, 2700 (2024).","journal-title":"Nat. Commun."},{"key":"2796_CR58","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1681\/ASN.0000000649","volume":"36","author":"HC Yu","year":"2025","unstructured":"Yu, H. C. et al. p21-Activated kinase 4 and ischemic acute kidney injury in mice and humans. J. Am. Soc. Nephrol. 36, 1264\u20131277 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2796_CR59","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1097\/HEP.0000000000000456","volume":"80","author":"M Mallet","year":"2024","unstructured":"Mallet, M. et al. Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis. Hepatology 80, 1270\u20131290 (2024).","journal-title":"Hepatology"},{"key":"2796_CR60","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s12276-026-01645-y","volume":"58","author":"IH Bang","year":"2026","unstructured":"Bang, I. H., Park, B. H. & Bae, E. J. PAK4 in metabolic diseases: regulation by nutrient signals and therapeutic implications. Exp. Mol. Med. 58, 416\u2013424 (2026).","journal-title":"Exp. Mol. Med."},{"key":"2796_CR61","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1158\/0008-5472.CAN-15-3373","volume":"76","author":"HT Xu","year":"2016","unstructured":"Xu, H. T. et al. PAK4 phosphorylates p53 at serine 215 to promote liver cancer metastasis. Cancer Res. 76, 5732\u20135742 (2016).","journal-title":"Cancer Res."},{"key":"2796_CR62","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3350\/cmh.2020.0178","volume":"26","author":"Y Liu","year":"2020","unstructured":"Liu, Y., Wang, X. & Yang, Y. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma. Clin. Mol. Hepatol. 26, 742\u2013750 (2020).","journal-title":"Clin. Mol. Hepatol."},{"key":"2796_CR63","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/13543776.2021.1944100","volume":"31","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. Drug discovery targeting p21-activated kinase 4 (PAK4): a patent review. Expert Opin. Ther. Pat. 31, 977\u2013987 (2021).","journal-title":"Expert Opin. Ther. Pat."},{"key":"2796_CR64","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.cmet.2023.06.013","volume":"35","author":"H Rho","year":"2023","unstructured":"Rho, H., Terry, A. R., Chronis, C. & Hay, N. Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis. Cell Metab. 35, 1406\u20131423.e1408 (2023).","journal-title":"Cell Metab."},{"key":"2796_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13817","volume":"7","author":"CY Han","year":"2016","unstructured":"Han, C. Y. et al. Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt. Nat. Commun. 7, 13817 (2016).","journal-title":"Nat. Commun."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02796-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02796-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02796-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:01:57Z","timestamp":1785366117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02796-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2796"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02796-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"297"}}